Big Pharma braces for the next price cut

The second round of Inflation Reduction Act drug price negotiations is expected to yield steeper discounts, with a potential early announcement of 2027 prices before the statutory November 30 deadline. Goldman Sachs projects a 50% discount for Novo Nordisk's semaglutide family, though its impact on Wegovy's obesity sales is limited by existing Part D restrictions, potentially favoring Eli Lilly's rival treatments. Teva's Austedo is forecast to see a 30% price cut, resulting in flat 2027 sales. Despite these targeted reductions, Goldman anticipates a muted overall impact on biopharma sector valuations, as policy risk is largely factored in, with long-term investment cases driven more by pipelines and execution.

Analysis

The second round of Inflation Reduction Act (IRA) drug price negotiations is poised to deliver steeper discounts than the initial round's average of 22%, with a potential early announcement before the statutory November 30 deadline creating headline risk. Goldman Sachs analysis highlights specific vulnerabilities, forecasting a significant 50% price reduction for Novo Nordisk's semaglutide franchise (Ozempic, Wegovy, Rybelsus). However, the practical impact on Wegovy's obesity sales is expected to be limited, as its Medicare Part D coverage is restricted to patients with cardiovascular disease. This dynamic may create a competitive advantage for Eli Lilly, whose rival treatments Mounjaro and Zepbound could become more attractive to health plans seeking alternative drugs with more flexible rebate potential. Teva Pharmaceutical's Austedo is also a focal point, with an anticipated 30% price hit projected to flatten its 2027 sales growth, countering the company's guidance on market penetration. Despite these targeted pressures, the broader biopharma sector impact is viewed as muted. Valuations already reflect a steep discount to the S&P 500, suggesting policy risk is largely priced in, shifting the long-term investment focus for companies like AstraZeneca and GSK back to fundamentals such as pipelines, patent cliffs, and commercial execution.

Key Decisions for Investors

• Investors holding Teva and Novo Nordisk should anticipate near-term stock volatility driven by the expected deep price cuts to Austedo and the semaglutide family, respectively.
• Consider that Eli Lilly is positioned as a potential relative winner, as mandated price reductions on competing Novo Nordisk drugs could strengthen the formulary placement and negotiating power of its Mounjaro and Zepbound treatments.
• Look beyond the immediate pricing headlines for the broader biopharma sector, as the analysis suggests policy risk is already priced into current discounted valuations, making long-term fundamentals like clinical pipelines the primary value drivers for names like AstraZeneca and GSK.
• Monitor for a potential early announcement of the 'maximum fair price' list ahead of the November 30 deadline, as this would be a significant catalyst for idiosyncratic moves in the affected stocks.